ForeSENTIA is a new generation test that identifies genetic alterations involved in cancer. It consists of an extensive portfolio of cancer panels, which provide accurate molecular analysis of the tumor sample taken during biopsy. There are two panel categories, both of which offer indispensable prognostic value, guidance on treatment decisions and increased chance of successful treatment through precision medicine and targeted therapies.

Comprehensive tumor profile panels: Wider coverage of genes implicated in specific cancer types

Therapy-associated tumor profile panels: for selected clinically actionable alterations that are related to targeted therapies.

ADVANTAGES OF ForeSENTIA:

  • Extensive analysis of clinically actionable genetic alterations
  • Detailed molecular classification of the tumor
  • Targeted therapy selection guidance
  • Improved prognostic assessment
  • Informed clinical management
  • Precision technology
  • High sensitivity & specificity

WHAT WILL THE ForeSENTIA REPORT TELL ME?

POSITIVE / NEGATIVE RESULT ON GENETIC ALTERATIONS TESTED

GUIDANCE ON APPROVED TARGETED THERAPIES AND CLINICAL TRIALS

COMPREHENSIVE ANALYSIS ON FINDINGS

COMPREHENSIVE TUMOR PROFILE PANELS

for wide coverage of genes implicated in specific cancer types

Comprehensive tumor profile panels test for an extensive number of clinically actionable genetic alterations that are frequently implicated in solid tumors; therefore giving the healthcare provider a complete molecular profile of the tumor.

  • Detailed molecular classification
  • Deep investigation of tumor heterogeneity
  • Better chances of identifying disease-causing variants

  • BREAST / OVARIAN

    44

  • COLORECTAL

    33

  • LUNG (NSCLC)

    35

  • PROSTATE

    27

  • MELANOMA

    21

  • GLIOMA

    22*

  • PAN-CANCER

    76*

* 1p/19q codeletion is also tested in these panels and reported only in the context of glioma diagnosis.

BREAST/OVARIAN TUMOR PROFILE PANEL

Description

The ForeSENTIA breast/ovarian tumor profile panel tests for numerous genetic alterations that are frequently found in breast or ovarian tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with breast or ovarian cancer can have tumor profile testing with the ForeSENTIA breast/ovarian panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

44

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA beast/ovarian tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.

ForeSENTIA Breast/Ovarian Tumor Profile Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Translocations
AKT1, ATM, BARD1, BRAF, BRCA1, BRCA2, BRIP1, CHEK2, CTNNB1, DICER1, EGFR, ERBB2, ERBB3, ESR1, FBXW7, FOXA1, FOXL2, GATA3, KIT, KRAS, MAP3K1, MRE11A, MTOR, NBN, NRAS, PALB2, PIK3CA, PIK3CB, POLE, PTEN, RAD51C, RAD51D, RAF1, RET, RUNX1, SMAD4, TP53 EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, KRAS, MET, PIK3CA, PTEN, TP53 NTRK1, NTRK2, NTRK3

COLORECTAL TUMOR PROFILE PANEL

Description

The ForeSENTIA colorectal tumor profile panel tests for numerous genetic alterations that are frequently found in colorectal tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with colorectal cancer can have tumor profile testing with the ForeSENTIA colorectal cancer panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

33

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA colorectal tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.

ForeSENTIA Colorectal Tumor Profile Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Translocations
AKT1, APC, ATM, BRAF, BRCA1, BRCA2, CTNNB1, EGFR, ERBB2, FBXW7, GNAS, KRAS, MLH1, MSH2, MSH6, MTOR, NRAS, NTRK1, PALB2, PIK3CA, PIK3CB, PMS2, POLE, PTEN, RAF1, SMAD4, TP53 EGFR, ERBB2, FGFR1, FGFR2, FGFR3, KRAS, MET, TP53 NTRK1, NTRK2, NTRK3

LUNG (NSCLC) TUMOR PROFILE PANEL

Description

The ForeSENTIA lung (NSCLC) tumor profile panel tests for numerous genetic alterations that are frequently found in lung (Non Small Cell Lung Cancers – NSCLC) tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with lung (NSCLC) cancer can have tumor profile testing with the ForeSENTIA lung (NSCLC) panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

35

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA lung (NSCLC) tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.

ForeSENTIA Lung (NSCLC) Tumor Profile Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Translocations
AKT1, ALK, APC, ARAF, ATM,BRAF, BRCA2, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, FBXW7, JAK2, KEAP1, KRAS, MAP2K1, MET, NRAS, PIK3CA, POLE, PTEN, RAF1, SMAD4, STK11, TP53 EGFR, ERBB2, FGFR1, FGFR2, FGFR3, MET, PIK3CA, PTEN, TP53 ALK, FGFR3, NTRK1, NTRK2, NTRK3, RET, ROS1

MELANOMA TUMOR PROFILE PANEL

Description

The ForeSENTIA melanoma tumor profile panel tests for numerous genetic alterations that are frequently found in melanomas. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with melanoma cancer can have tumor profile testing with the ForeSENTIA melanoma panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

21

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA melanoma tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.

ForeSENTIA Prostate Tumor Profile Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Translocations
AKT1, BRAF, CTNBB1, ERBB2, GNA11, GNAQ, KIT, KRAS, MAP2K1, NF1, NRAS, PIK3CA, POLE, PTEN, TP53 ERBB2, KIT, KRAS, MYC, TP53 ALK, BRAF, NTRK1, NTRK2, NTRK3, RET, ROS1

PROSTATE TUMOR PROFILE PANEL

Description

The ForeSENTIA prostate tumor profile panel tests for numerous genetic alterations that are frequently found in prostate tumors. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with prostate cancer can have tumor profile testing with the ForeSENTIA prostate panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

27

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA prostate tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.

ForeSENTIA Prostate Tumor Profile Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Translocations
AKT1, APC, AR, ATM, BRAF, BRCA1, BRCA2, CTNNB1, FOXA1, NRAS, PALB2, PIK3CA, PIK3CB, POLE, PTEN, SPOP, TP53 AR, ERBB2, FGFR1, FGFR2, FGFR3, MYC, MYCN, PIK3CA, PTEN, RB1, TP53 TMPRSS2

GLIOMA TUMOR PROFILE PANEL

Description

The ForeSENTIA glioma tumor profile panel tests for numerous genetic alterations that are frequently found in gliomas. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with glioma cancer can have tumor profile testing with the ForeSENTIA glioma panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

22

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA glioma tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.

ForeSENTIA Glioma Tumor Profile Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Translocations
ATRX, BRAF, CIC, CTNNB1, EGFR, FUBP1, H3F3A, IDH1, IDH2, NF1, POLE, TERT, TP53 1p/19q codeletion, CDKN2A, EGFR, MET, MYC, MYCN, PTEN BRAF, FGFR3, NF1, NTRK1, NTRK2, NTRK3

PAN-CANCER TUMOR PROFILE PANEL

Description

The ForeSENTIA pan-cancer tumor profile panel tests for numerous genetic alterations that are frequently found in several cancers. Identifying the genetic alterations that have led to cancer development can empower the healthcare provider with clinically actionable and therapeutic information and allow them to tailor medical treatment to each tumor’s unique characteristics.

Who is this test for?

Any patient diagnosed with cancer can have tumor profile testing with the ForeSENTIA pan-cancer panel to help identify the specific genetic alterations that are associated with their tumor.

Number Of Genes Tested

76

Sample: Unstained sections from tumor biopsy sample

Turnaround time: 2-3 Weeks

Genes Tested

The table below shows the genes tested by the ForeSENTIA pan-cancer tumor profile panel, and whether the genes examined are tested for Single Nucleotide Variants, Insertions and Deletions, Copy Number Alterations, Translocations or a combination of variants.

ForeSENTIA Pan-Cancer Tumor Profile Panel

Single Nucleotide Variants / Insertions and Deletions Copy Number Alterations Translocations
AKT1, ALK, APC, AR, ARAF, ATM, ATRX, BARD1, BRAF, BRCA1,BRCA2, BRIP1, CHEK2, CIC, CTNNB1,DDR2, DICER1, EGFR, ERBB2, ERBB3, ERBB4, ESR1, FBXW7, FOXA1, FOXL2, FUBP1, GATA3,GNA11, GNAQ, GNAS, H3F3A, IDH1, IDH2, JAK2, KEAP1, KIT, KRAS, MAP2K1, MAP3K1, MET, MLH1, MRE11A, MSH2, MSH6, MTOR, NBN, NF1, NRAS, NTRK1, PALB2, PIK3CA, PIK3CB, PMS2, POLE, PTEN, RAD51C, RAD51D, RAF1, RET, RUNX1, SMAD4, SPOP, STK11, TERT, TP53 1p/19q codeletion, AR, CDKN2A, EGFR, ERBB2, ESR1, FGFR1, FGFR2, FGFR3, KIT, KRAS, MET, MYC, MYCN, PIK3CA, PTEN, RB1, TP53 ALK, BRAF, FGFR3, NF1, NTRK1, NTRK2, NTRK3, RET, ROS1, TMPRSS2

THERAPY-ASSOCIATED TUMOR PROFILE PANELS

for selected clinically actionable alterations that are related to targeted therapies

Therapy-associated tumor profile panels test for single nucleotide variants (SNVs), insertions and deletions on selected hotspot regions of 1 or 2 genes that are frequently involved in a variety of tumors. Testing of these genes is routinely requested by healthcare professionals due to their implication in tumors. There are several approved* targeted therapies and ongoing clinical trials focusing on these genes.

  • Clinically-actionable, therapy-related alterations
  • Shorter turn-around time
EGFR
Cancers:
Lung
Melanoma
Endometrial
Colorectal
Adenocarcinoma
Breast
KRAS+NRAS
Cancers:
Pancreatic
Colorectal
Lung
Melanoma
Thyroid
Bladder
Endometrial
Thymoma
Testicular
PIK3CA+AKT1
Cancers:
Breast
Endometrial
Colorectal
Cervical
Head and Neck
Bladder
Lung
BRAF
Cancers:
Melanoma
Thyroid
Colorectal
Endometrial
Lung
IDH1+IDH2
Cancers:
Glioma

*FDA (Food and Drug Administration), EMA (European Medicines Agency), PMDA (Pharmaceuticals and Medical Devices Agency, Japan) HCSC (Health Canada Santé Canada)

WHY RECOMMEND ForeSENTIA TO MY PATIENTS?

By thoroughly analyzing the tumor sample for clinically actionable genetic alterations involved in carcinogenesis, ForeSENTIA allows targeted and precise patient treatment.

With ForeSENTIA, you ensure that your patients will have the best therapy option for them - which will improve their chances of survival.

WHAT CAN I DO TO HELP MY PATIENTS AFTER ForeSENTIA?

With the information gained by ForeSENTIA, you will be able to:

  • Prescribe the most suitable therapies for your patients
  • Provide your patients accurate prognosis
  • Identify appropriate clinical trials to enroll your patient

WHAT DOES ForeSENTIA DETECT?

ForeSENTIA detects the 4 main types of genetic alterations known to be implicated in cancer:

Click here to view the table of genes tested by the ForeSENTIA Tumor Profile Panels, and whether the genes examined are tested for Single Nucleotide Variants(SNVs) / Insertions and Deletions, Copy Number Alterations (CNAs), translocations or a combination of variants

WHY CHOOSE ForeSENTIA?

ForeSENTIA thoroughly analyzes the tumor sample for numerous clinically actionable mutated genes involved in cancer development. It is cost effective, time sensitive and clinically valuable.

WHAT ARE THE BENEFITS FOR MY PATIENTS?

  • Ability to select a panel that is most suitable to them
  • Knowledge of eligible clinical trials
  • Invaluable prognostic insight
  • Lower risk of ineffective therapy and adverse effects
  • Higher chances of successful treatment and survival

TECHNOLOGY YOU TRUST

ForeSENTIA uses novel, target capture enrichement technology proven for its precision and accuracy. Analysis of selection regions is performed at an extremely high read-deapth, improving the statistical accuracy of the results. Lastly, genetic and bioinformatics approaches, and multi-engine analysis pipelines have been specifically incorporated to raise the sensitivity and specificity of ForeSENTIA.

TARGETED TECHNOLOGY

ForeSENTIA is based on a novel, target capture enrichment technology that has been validated for its accuracy and precision.

HIGH READ DEPTH

Specifically-designed analytical methods have been incorporated to ensure high read-depth, raising the sensitivity and specificity of the test.

MULTI-ENGINE ANALYSIS

Proprietary bioinformatics pipelines analyze the sequencing data produced from each sample, increasing the sensitivity and specificity of ForeSENTIA

WHAT IS THE POSITION OF PROFESSIONAL BODIES ON PRECISION MEDICINE?

Molecular tumor profiling has become a routine part of cancer patient care. It can help healthcare providers avoid a ‘one-size-fits-all’ approach and instead choose tailored treatments that improve survival chances for cancer patients and spare them potential side effects from drugs that are unlikely to be beneficial. Such advancements in technology and genomics can help physicians in diagnosing, treating and understanding more about human disease, and in selecting treatment that is most likely to help patients.

Source: Food and Drug Administration (FDA), National Comprehensive Cancer Network (NCCN), American Cancer Society, European Society for Medical Oncology (ESMO), Cancer.Net and National Cancer Institute

HOW TO ADMINISTER ForeSENTIA?

  • RECOMMEND THE IDEAL PANEL TO YOUR PATIENT
  • LET THE HISTOPATHOLOGY LAB KNOW THAT ADDITIONAL TESTING WILL BE REQUIRED ON THE TISSUE BIOPSY SAMPLE
  • THE HISTOPATHOLOGY LAB WILL SEND US THE TUMOR SECTIONS
  • THE RESULTS WILL BE SENT TO YOU IN 2-3 WEEKS

Depending on the results, guidance on finding the most appropriate targeted therapies and clinical trials will be provided.

Other Products

NIPD Genetics - Privacy Policy

General Statement

This Privacy Policy applies only to www.nipd.com and its subdomains (hereafter collectively referred to as “Sites") that link to this policy. NIPD Genetics Sites are owned by NIPD Genetics Public Company Ltd and are operated by NIPD Genetics Public Company Ltd and on occasion by a third-party that is responsible for the technical maintenance of the Sites.

If, you do not agree with this Privacy Policy, please do not access or use any of NIPD Genetics Sites.

NIPD Genetics values your interest in NIPD Genetics, its products and its services. NIPD Genetics takes the protection of your data seriously.

Personal data for purposes of this Privacy Policy, is any information by which you can be individually identified, including, but not limited to, your name, profession, address, e-mail address, and telephone number.

You may contact NIPD Genetics Public Company Ltd at
NIPD Genetics Public Company Ltd
Neas Engomis 31
Engomi, Nicosia
2409, Cyprus

NIPD Genetics Data Protection Officer can be reached at dpo@nipd.com

This Privacy Policy applies only to the Sites as defined above and which are operated by NIPD Genetics. The NIPD Genetics Privacy Policy seeks to inform the users of its Sites of the following:

NIPD Genetics will not use or share your information with anyone, except as described in this Privacy Policy. This Privacy Policy does not apply to any information we might collect by other digital and offline means and or from other digital and offline sources. The use of information collected through our Sites shall be limited to the purposes under this Privacy Policy and our Terms of Use to customers.

This page informs you of our policies regarding the collection, use, and disclosure of personal data when you use our Sites and the choices you have associated with that data.

We use your data to provide and improve the Sites. By using the Sites, you agree to the collection and use of information in accordance with this policy. Unless otherwise defined in this Privacy Policy, terms used in this Privacy Policy have the same meanings as in our Terms and Conditions, accessible from www.nipd.com

Type of personal information NIPD Genetics may collect through its Sites

Information Collection And Use

We collect several different types of information for various purposes to provide and improve our Sites and services to you.

Personal Data

While using NIPD Genetics Sites, you may be asked to provide NIPD Genetics certain personally identifiable information that can be used to contact or identify you ("Personal Information"). Personal Information that might be used to identify you includes, but is not limited to:

If you send us a query via our Contact us form, your email address, the content and any follow up emails are retained indefinitely.

Cookies and Usage Data

Usage Data

We may also collect information how the Sites are accessed and used ("Usage Data"). This Usage Data may include information such as your computer's Internet Protocol address (e.g. IP address), browser type, browser version, the pages of our Sites that you visit, the time and date of your visit, the time spent on those pages, unique device identifiers and other diagnostic data.

Tracking & Cookies Data

We use cookies and similar tracking technologies to track the activity on our Sites and hold certain information.

Cookies are files with small amount of data which may include an anonymous unique identifier. Cookies are sent to your browser from a website and stored on your device. Tracking technologies also used are beacons, tags, and scripts to collect and track information and to improve and analyze our Sites.

You can instruct your browser to refuse all cookies or to indicate when a cookie is being sent. However, if you do not accept cookies, you may not be able to use some portions of our Sites.

Examples of Cookies we use:

Session Cookies. We use Session Cookies to operate our Sites.

Preference Cookies. We use Preference Cookies to remember your preferences and various settings.

Security Cookies. We use Security Cookies for security purposes.

Visitor behavior cookies. To understand how visitors use and navigate the Sites

Keyword cookies. To understand how visitors discover the Sites.

Use of Data

www.nipd.com uses the collected data for various purposes:

Transfer of Data

Your information, including personal data, may be transferred to — and maintained on — computers located outside of your province, country or other governmental jurisdiction where the data protection laws may differ than those from your jurisdiction.

If you are located outside Cyprus and choose to provide information to us, please note that we transfer the data, including personal data, to Cyprus and process it there.

Your consent to this Privacy Policy followed by your submission of such information represents your agreement to that transfer.

www.nipd.com will take all reasonable steps necessary to ensure that your data is treated securely and in accordance with this Privacy Policy and no transfer of your personal data will take place to an organization or a country unless there are adequate controls in place including the security of your data and other personal information.

Disclosure of Data

NIPD Genetics complies with the protection of personal data regulation and will not sale or trade your personal data.

NIPD Genetics may disclose your personal data in the good faith belief that such action is necessary to:

Security of Data

The security of your data is important to us, but remember that no method of transmission over the Internet, or method of electronic storage is 100% secure. While we strive to use commercially acceptable means to protect your Personal Data, we cannot guarantee its absolute security.

Service Providers

We may employ third party companies and individuals to facilitate, maintain or operate our Sites ("Service Providers"), to provide the SItes on our behalf, to perform service-related services or to assist us in analyzing how our Sites is used.

These third parties have access to your Personal Data only to perform these tasks on our behalf and are obligated not to disclose or use it for any other purpose.

Analytics

We may use third-party Service Providers to monitor and analyze the use of our Sites.

Google Analytics

Google Analytics is a web analytics service offered by Google that tracks and reports website traffic. Google uses the data collected to track and monitor the use of our Service. This data is shared with other Google services. Google may use the collected data to contextualize and personalize the ads of its own advertising network.

You can opt-out of having made your activity on the Service available to Google Analytics by installing the Google Analytics opt-out browser add-on. The add-on prevents the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) from sharing information with Google Analytics about visits activity.

For more information on the privacy practices of Google, please visit the Google Privacy & Terms web page

Access to your personal data, correction, deletion, and Opting Out

You have the right to review, update or delete any of your personal data by sending a request at NIPD Genetics Personal Data Officer pdo@nipd.com

Links to Other Sites

Our Sites may contain links to other sites that are not operated by us. If you click on a third-party link, you will be directed to that third party's site. We strongly advise you to review the Privacy Policy of every site you visit.

We have no control over and assume no responsibility for the content, privacy policies or practices of any third-party sites or services.

Children's Privacy

Our Service does not address anyone under the age of 18 ("Children").

We do not knowingly collect personally identifiable information from anyone under the age of 18. If you are a parent or guardian and you are aware that your Children has provided us with Personal Data, please contact us. If we become aware that we have collected Personal Data from children without verification of parental consent, we take steps to remove that information from our servers.

Changes to This Privacy Policy

We may update our Privacy Policy from time to time. We will notify you of any changes by posting the new Privacy Policy on this page.

We will let you know via email and/or a prominent notice on our Service, prior to the change becoming effective and update the "effective date" at the top of this Privacy Policy.

You are advised to review this Privacy Policy periodically for any changes. Changes to this Privacy Policy are effective when they are posted on this page.

Contact Us

If you have any questions about this Privacy Policy, please contact pdo@nipd.com

Ok got it!